Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sequential phenotyping of myeloma patients on chemotherapy: persistence of activated T-cells and natural killer cells.

Leukemia & lymphoma - 1 Jan 1995

Kay N E, Oken M M, Kyle R, Van Ness B, Kalish L, Leong T, Greipp P

Abstract excerpt

To better detail the status of functional T cell subsets and natural killer cells in multiple myeloma, we undertook a detailed immunophenotypic study of circulating mononuclear cells in myeloma. We studied myeloma patients entered on a large prospective, randomized ECOG chemotherapy trial EST 9486 for patients with newly diagnosed multiple myeloma. All patients were studied prior to entry and then two months...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Flow Cytometry
Share to Follow-Up Studies
Share to Immunoglobulin G

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Killer Cells, Natural

Share to Lymphocyte Activation

Share to Lymphocytes

Share to Phenotype

Share to T-Lymphocytes

Source

Identifiers

PMID: 7719242
DOI: 10.3109/10428199509049775

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sequential phenotyping of myeloma patients on chemotherapy: persistence of activated T-cells and natural killer cells.PMID 7719242Read ↗

T-helper phenotypes in the blood of myeloma patients on ECOG phase III trials E9486/E3A93.Semantic proximity Read ↗

Single-cell transcriptomic analysis of NK cell dynamics in myeloma patients reveal persistent reduction of cytotoxic NK cells from diagnosis to relapseSemantic proximity Read ↗

Immune Phenotypes and Target Antigens of Clonally Expanded Bone Marrow T Cells in Treatment-Naïve Multiple Myeloma.Semantic proximity Read ↗

T‐cell expansions in patients with multiple myeloma have a phenotype of cytotoxic T cellsSemantic proximity Read ↗

Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myelomaSemantic proximity Read ↗

FcεRIγ-negative NK cells persist in vivo and enhance efficacy of therapeutic monoclonal antibodies in multiple myelomaSemantic proximity Read ↗

Monitoring the cytogenetic architecture of minimal residual plasma cells indicates therapy-induced clonal selection in multiple myelomaSemantic proximity Read ↗

Bone marrow PMN-MDSCs and neutrophils are functionally similar in protection of multiple myeloma from chemotherapy.Semantic proximity Read ↗

Molecular mechanisms promoting long-term cytopenia after BCMA CAR-T therapy in Multiple MyelomaSemantic proximity Read ↗

Clonal cytotoxic T cells in myeloma.Semantic proximity Read ↗

Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components.Semantic proximity Read ↗

Isolation and characterization of human multiple myeloma cell enriched populations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.